PDS Biotechnology (PDSB) Fundamental Analysis: Revenue, Earnings & Valuation

3.70 / 10

Netural

Fundamental health is subpar, scoring 3.7/10. Positive drivers include strong cash‑to‑market (Cash‑MV) and high inventory turnover. Weak points are low PB‑ROE, negative Revenue‑MV, and modest income‑tax‑to‑profit ratio, leading to a guarded outlook.

Analysis Checks(6/10)

Revenue-MV

Value-0.28

Score1/3

Weight12.88%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value78.03

Score3/3

Weight3.33%

1M Return1.54%

Inventory turnover ratio

Value47.95

Score3/3

Weight17.09%

1M Return6.74%

Gross profit margin (%)

Value36.92

Score1/3

Weight-1.21%

1M Return-0.63%

PB-ROE

Value0.25

Score0/3

Weight8.60%

1M Return3.23%

Income tax / Total profit (%)

Value4.16

Score1/3

Weight-0.99%

1M Return-0.50%

Fixed assets turnover ratio

Value7895.57

Score3/3

Weight2.20%

1M Return1.06%

Cost of sales ratio (%)

Value70.31

Score3/3

Weight9.88%

1M Return4.32%

Asset-MV

Value-0.49

Score2/3

Weight33.04%

1M Return12.22%

Cash-MV

Value-0.09

Score2/3

Weight15.18%

1M Return5.94%

Is PDSB fundamentally strong?

PDSB scores 3.70/10 on fundamentals and holds a Fair valuation at present. Backed by its -189.28% ROE, 0.00% net margin, -0.82 P/E ratio, 3.02 P/B ratio, and 30.77% earnings growth, these metrics solidify its Netural investment rating.